|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 384.32 USD | +4.49% |
|
+12.41% | +17.42% |
| 02-06 | Guggenheim Adjusts Price Target on Amgen to $347 From $305, Maintains Neutral Rating | MT |
| 02-06 | Argus Research Adjusts Price Target on Amgen to $400 From $360, Maintains Buy Rating | MT |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Human Therapeutics | 25.42B | 25.98B | 26.32B | 28.19B | 33.42B | |||||
Total Assets | 62.95B | 61.16B | 65.12B | 97.15B | 91.84B | |||||
Interest Expense | -1.04B | -1.2B | -1.41B | -4.08B | -3.66B | |||||
Income Tax Expense | 869M | 808M | 794M | 1.14B | 519M | |||||
CAPEX | -608M | -880M | -936M | -1.11B | -1.1B | |||||
EBT | 8.13B | 6.7B | 7.35B | 7.86B | 4.61B | |||||
D&A | 3.44B | 3.24B | 3.42B | 4.07B | 5.59B | |||||
Operating Income | 9.14B | 7.64B | 9.57B | 7.9B | 7.26B | |||||
Net Income | 7.26B | 5.89B | 6.55B | 6.72B | 4.09B |
Geographical Revenue Distribution History
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
United States (U.S.) | 18.5B | 18.19B | 18.6B | 19.81B | 23.86B | |||||
Total Assets | 2.47B | 2.8B | 3.15B | 3.66B | 4.16B | |||||
Rest of The World (Row) | 6.93B | 7.78B | 7.73B | 8.38B | 9.56B | |||||
Total Assets | 1.08B | 1.07B | 1.03B | 1.14B | 1.21B | |||||
Total Assets | 1.33B | 1.31B | 1.25B | 1.15B | 1.17B |
- Stock Market
- Equities
- AMGN Stock
- Financials Amgen Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition